

# **Prosjektoppgave i medisin**

**Universitetet i Oslo, 2009**

**Skrevet av  
Amir David Arden**

## **Transient nephritis during resolution phase of acute virale hepatitis E**

### **Abstract**

Hepatitis E Virus is a causative agent of hepatitis. Viral E hepatitis is responsible for various clinical manifestations. However, immune reactions due to hepatitis E virus are rarely encountered. A case of membranoproliferative glomerulonephritis associated with hepatitis E virus is reported her.

### **Introduction**

Viral Hepatitis is a major public health problem worldwide. The hepatitis is a disease that can be caused by five unrelated human viruses, namely, hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D (HDV) and hepatitis E (HEV). Table 1 summarizes the outcome of the different viruses. Hepatitis E was not recognized as distinct clinical entity until 1980, previously known as enterically transmitted non-A, non-B hepatitis (NANBH). Hepatitis E is caused by infection with the hepatitis E Virus, a non-enveloped single-stranded, linear, positive sense, polyadenenylated RNA (7,5kb). Structural and physiochemical properties, the hepatitis E virus have been classified in the family Caliciviridae, genus Calicivirus. The hepatitis E virus is seen in epidemic outbreak in regions where low standards of sanitation promote the transmission of the virus. Epidemics of hepatitis E have been reported in Southern and Central asia, North and West Africa, Middle East, an in parts of Mexico. It is also seen as sporadic disease in many parts of the world often in travellers returning from abroad. The incubation period following exposure to hepatitis E virus range for 2 to 10 weeks. It is a self – limiting disease followed by recovery and typically lasts 1-4 weeks, chronic infection was until recently thought not to occur. Typical signs and symptom of hepatitis include jaundice, anorexia, hepatomegaly, abdominal pain and tenderness, fever, mild chills, nausea, vomiting, clay-coloured stools, dark coloured urine, diarrhoea, arthralgia, although the disease may range in severity from sub clinical to fulminant form with overall patient population mortality rates ranging between 0,5-4%, and as 10-40% among pregnant women. During outbreaks the infection is most common among adults aged 15-40 years (3-30%) than among children (0,2-10%). Hepatitis B and C Virus infection is associated with membranoproliferative glomerulonephritis. Membranoproliferative glomerulonephritis is a kidney disorder that may be related to immune system function. There has only once, been reported membranoproliferative glomerulonephritis due to acute hepatitis E virus. We report a patient with acute hepatitis E virus that developed membranoproliferative glomerulonephritis.

### **Case Report**

A 25 year old man was admitted to Ullevål University Hospital on March 14, 2008, with a thirty day history of mild diarrhoea and 10 days dark urine, on control 3 days later the patient had fever, loss of appetite, nausea, vomiting and upper abdominal pain. He was of Arabic origin, lived in Norway and with recently travel history to an endemic area within six to eight weeks prior to symptom onset. The patient had a non-organised individual travel to India and Nepal in December, January and February, the length of his stay ranged 9 weeks. The patient had been healthy during the travel, however 1 week prior to departure, after staying three days along the Varanasi River in North-India, the patient had a history of reported vomiting and flu-like syndrome, cough, low grade fever and night sweats, this condition lasted for three days. The patient was hepatitis A and hepatitis B vaccinated.

Physical examination revealed splenomegaly, tenderness in the right hypochondrium, and severe jaundice. Abnormal laboratory findings included an International Normalized Ratio (INR) at 2.1. Liver dysfunction was seen, with an increase in levels of aspartate aminotransferase (5665 U/L), alanine aminotransferase (6959 U/L), lactate dehydrogenase (617 U/L), alkaline phosphatase (363 U/L), glutamyltransferase and total bilirubin (468 µmol/l). Serum immunoglobulin G levels were relatively elevated (15,3 g/L). No antibodies against human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) were not detected, instead Anti-HEV IgG was detected with Genelabs Diagnostics HEV Elisa. Antibodies against smooth muscle (SMA) were detected, and SMA titer revealed 64, however ANA ELISA, AMA, Anti-LKM1, RF, IgA RF ELISA, IgM RF ELISA, Anti-CCP, C-ANCA screen, P-ANCA screen, Anti-PR3, Anti-MPO were all negative. Chest X-ray was normal. Abdominal ultrasonography taken 18.03.08, showed hepatomegaly, no thickened gallbladder and splenomegaly. The kidney basement membrane showed no pathology. The patient was treated conservatively.

On the twentieth day the patient improved considerably. His liver function test showed serum aspartate aminotransferase (143 U/L), alanine aminotransferase (522 U/L) and bilirubin (94 µmol/l). However the patient started to describe the manifestation of kidney pain (severe back ache). Ibuprofen medical treatment relieved immediately the symptoms of kidney pain. Urine Microbiological Bacterial Cultures revealed no bacterial nephritis. A new abdominal ultrasonography taken 01.04.08 demonstrated normal sized kidneys with widespread thickening of the kidney basement membrane, compatible with renal membranoproliferative glomerulonephritis. A renal biopsy was not performed. The patient's initial urinalysis was positive for blood and leukocytes. Dipstick urinalysis revealed blood ++++, and leukocytes +(+), Urine light microscope provided further confirmation of haematuria and leukocytes. He had no hypertension and no decline in renal function. Full blood count revealed no other than hepatitis E virus infection.

He was discharged from hospital, followed up, and received no other medication than Ibuprofen. During follow up of six months, the patient kept well and liver function, kidney function test were normal.

## Discussion

Most autochthonous hepatitis E virus infections are self-limiting, acute icteric hepatitis; however, follow-up studies of 40 hepatitis E virus infected patients demonstrated that six (15 %) patients developed complications. The clinical features of autochthonous hepatitis E infection range from asymptomatic infection to mild hepatitis, to subacute liver failure. Studies based on affected individuals have presented a range of other non-hepatic symptoms, however these studies have not yet revealed infected patient with acute hepatitis E virus, that develop membranoproliferative

glomerulonephritis. Although one of the most frequent kidney diseases associated with chronic hepatitis C virus (HCV) and B virus is membranoproliferative glomerulonephritis. Membranoproliferative glomerulonephritis due to hepatitis virus is still a poorly understood disease. To our knowledge Hepatitis E Virus causing membranoproliferative glomerulonephritis, has only once been reported in a case report. Many associated infections have been reported to cause membranoproliferative glomerulonephritis, but none have been found in this patient. It is believed that the persistent infection with the hepatitis E virus (HEV) is responsible for an immune complex-mediated glomerulonephritis in this patient. Development of membranoproliferative glomerulonephritis in this patient with clinical hepatitis and positive serology for Anti-HEV IgG makes the cause and effect relationships of membranoproliferative glomerulonephritis with hepatitis E most likely.

The principal clinical manifestations of glomerulus's disease in hepatitis virus infected patients are the presence of proteinuria and microscopic haematuria with or without impaired kidney function, this patient had also demonstrated widespread thickening of the kidney basement membrane.

The clinical manifestations of membranoproliferative glomerulonephritis may be so variable that the disease is often diagnosed only if it has been systematically considered. Many times, it is diagnosed as a form of back pain. In a UK hospital-based study, 40 patient with autochthonous hepatitis E were identified, with affected individuals presenting a range of other non-specific symptoms, 2% describe the manifestation of back pain.

## **Conclusion**

Many cases of glomerulonephritis result in a mild, asymptomatic illness that remains undiagnosed.

Because hepatitis E virus has now been pathogenetically linked to glomerulonephritis in this patient, testing for this virus should be considered in the serologic work-up of patients with glomerulonephritis, particularly in countries with a high prevalence of hepatitis E virus, or patients with recent travel history to hepatitis E virus endemic countries.

## **References:**

1. Harry R. Dalton<sup>a</sup>, William Stableforth<sup>a</sup>, Prem Thuraiajah<sup>c</sup>, Simon Hazeldine<sup>d</sup>, Rene Remnarace<sup>e</sup>, Warshaw Usamac<sup>f</sup>, Liz Farrington<sup>a</sup>, Noor Hamada<sup>a</sup>, Cyril Sieberhagen<sup>f</sup>, Vic Ellis<sup>b</sup>, Jonathan Mitchell<sup>c</sup>, S. Hyder Hussain<sup>a</sup>, Malcolm Banks<sup>g</sup>, Samreen Ijaz<sup>h</sup> and Richard P. Bendall<sup>b</sup>. Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. *Eur J Gastroenterol Hepatol*

- 20:784–790 \_c 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins. *European Journal of Gastroenterology & Hepatology*
2. Harry R. Dalton, Richard Bendall, Samreen Ljaz, Malcolm Banks. Hepatitis E: an emerging infection in developed countries. *Lancet Infect Dis* 2008; 8: 698-709.
  3. Isa K. Mushahwar. Hepatitis E Virus: Molecular Virology, Clinical Features, Diagnosis, Transmission, Epidemiology, and Prevention. *Journal of Medical Virology* 80:646–658 (2008).
  4. Rakesh Aggarwal and Krzysztof Krawczynski. Hepatitis E: An overview and recent advances in clinical and laboratory research. *Journal of Gastroenterology and Hepatology* (2000) 15, 19-20.
  5. Amarapurkar DN, Amarapurkar AD. Extrahepatic manifestations of viral hepatitis. *Ann Hepatol.* 2002 Oct-Dec; 1(4): 192-5.
  6. Khin Saw Aye Myint, Robert V. Gibbons. Hepatitis E: a neglected threat. *Transactions of the Royal Society of Tropical Medicine and Hygiene* (2008) **102**, 211—212
  7. G Ali, M Kumar, SK Bali, WB Wadhwa. Hepatitis E associated immune thrombocytopaenia and membranous glomerulonephritis. *Indian J Nephrol* 2001;11: 70-72.
  8. Mrigendra Prasad Shrestha, M.B., B.S., Robert McNair Scott, M.D., Durga Man Joshi, M.D., Mammen P. Mammen, Jr., M.D., Gyan Bahadur Thapa, M.B., B.S., Narbada Thapa, Ph.D., Khin Saw Aye Myint, M.B., B.S., Marc Fourneau, B.S., Robert A. Kuschner, M.D., Sanjaya Kumar Shrestha, M.D., Marie Pierre David, M.S., Jitvimol Seriwatana, M.S., David W. Vaughn, M.D., Assad Safary, M.D., Timothy P. Endy, M.D., and Bruce L. Innis, M.D. Safety and Efficacy of a Recombinant Hepatitis E Vaccine. *N Engl J Med* 2007;356:895-903.